COHERE
Device
NUVASIVE, INC.
Total Payments
$4.0M
Transactions
1,618
Doctors
627
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $997,515 | 191 | 44 |
| 2023 | $1.2M | 128 | 54 |
| 2022 | $957,411 | 166 | 92 |
| 2021 | $614,756 | 270 | 120 |
| 2020 | $252,668 | 158 | 92 |
| 2019 | $10,986 | 270 | 168 |
| 2018 | $28,961 | 428 | 281 |
| 2017 | $233.55 | 7 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $3.5M | 241 | 86.6% |
| Unspecified | $403,293 | 105 | 10.0% |
| Food and Beverage | $53,347 | 1,135 | 1.3% |
| Consulting Fee | $48,569 | 51 | 1.2% |
| Travel and Lodging | $33,614 | 79 | 0.8% |
| Education | $106.51 | 4 | 0.0% |
| Entertainment | $37.14 | 3 | 0.0% |
Payments by Type
General
$3.6M
1,513 transactions
Research
$403,293
105 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NUVA.CIB0420: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine | NuVasive, Inc. | $127,264 | 0 |
| NUVA.CIB0420: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine | Globus Medical, Inc. | $75,221 | 0 |
| A Prospective, Multicenter Study Evaluating the Safety and Performance of Interbody Implants for the Treatment of Patients With Degenerative Conditions of the Cervical Spine | Globus Medical, Inc. | $58,521 | 0 |
| A Prospective, Multicenter Study Evaluating the Safety and Performance of Interbody Implants for the Treatment of Patients With Degenerative Conditions of the Cervical Spine (Enrolling by invitation) | Globus Medical, Inc. | $31,561 | 0 |
| A Prospective, Multicenter Study Evaluating the Safety and Performance of Interbody Implants for the Treatment of Patients With Degenerative Conditions of the Cervical Spine | NuVasive, Inc. | $27,252 | 0 |
| A Retrospective Review of the Clinical and Radiographic Outcomes Following the Use of the NuVasive Cervical Interbody Implants with Attrax Putty for Degenerative Cervical Pathologies | Globus Medical, Inc. | $24,000 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine | NuVasive, Inc. | $23,075 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $19,532 | 0 |
| A Prospective, Multicenter Study Evaluating the Safety and Performance of Interbody Implants for the Treatment of Patients With Degenerative Conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $8,489 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | Globus Medical, Inc. | $4,759 | 0 |
| NUVA.LIB1119 | NuVasive, Inc. | $1,950 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine (Enrolling by invitation) | NuVasive, Inc. | $1,670 | 0 |
Ad
Manufacturing Companies
- NuVasive, Inc. $3.0M
- Globus Medical, Inc. $997,515
- NUVASIVE, INC. $233.55
Product Information
- Type Device
- Total Payments $4.0M
- Total Doctors 627
- Transactions 1,618
About COHERE
COHERE is a device associated with $4.0M in payments to 627 healthcare providers, recorded across 1,618 transactions in the CMS Open Payments database. The primary manufacturer is NUVASIVE, INC..
Payment data is available from 2017 to 2024. In 2024, $997,515 was paid across 191 transactions to 44 doctors.
The most common payment nature for COHERE is "Royalty or License" ($3.5M, 86.6% of total).
COHERE is associated with 12 research studies, including "NUVA.CIB0420: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine" ($127,264).